Hydrochlorothiazide Metabolism and Renal Function
Hydrochlorothiazide is primarily eliminated unchanged by the kidneys through renal excretion and is not metabolized in the kidney or elsewhere in the body.
Pharmacokinetics of Hydrochlorothiazide
Absorption and Distribution
- Well absorbed (65-75%) following oral administration 1
- Peak plasma concentrations observed within 1-5 hours after dosing 1
- Plasma concentrations linearly related to administered dose 1
- Binding to serum proteins is approximately 40-68% 1
Elimination
- Plasma elimination half-life is 6-15 hours 1
- Eliminated primarily through renal pathways 1
- Following oral doses, 55-77% of the administered dose appears in urine 1
- Greater than 95% of the absorbed dose is excreted in urine as unchanged drug 1
- Not metabolized by the liver or kidneys - excreted unchanged in urine
Impact of Renal Function on Hydrochlorothiazide
Changes in Pharmacokinetics with Renal Impairment
- In patients with renal disease, plasma concentrations of hydrochlorothiazide are increased 1
- Elimination half-life is prolonged in renal impairment 1
- Reduced clearance leads to drug accumulation and potentially increased side effects
Clinical Implications
- Efficacy decreases as GFR falls below 30-40 ml/min 2
- Thiazides should be avoided alone when GFR <30 ml/min 2
- In advanced CKD, loop diuretics are preferred over thiazides due to better efficacy 2
Monitoring Considerations
Electrolyte and Renal Function Monitoring
- Monitor serum creatinine and electrolytes 1-2 weeks after initiation or dose changes 2
- Watch for hypokalemia, hypomagnesemia, and hyponatremia 2
- The greatest diuretic effect occurs within the first few days of administration, causing significant electrolyte shifts 3
Potential Adverse Effects
- Thiazides can cause hypokalemia, which may impair endothelium-dependent vasorelaxation 4
- HCTZ has been associated with metabolic abnormalities including hypertriglyceridemia, hyperglycemia, and insulin resistance 4
- Volume depletion from HCTZ can lead to hyperaldosteronism and potential renal injury 4
Clinical Pearls
- Unlike many drugs that undergo hepatic metabolism, hydrochlorothiazide's elimination is almost entirely dependent on renal function
- Dose adjustments or alternative diuretics should be considered in patients with significant renal impairment
- For patients with moderate-to-severe CKD (eGFR <30 mL/min), bumetanide is the preferred diuretic 2
- When using HCTZ in patients with mild renal impairment, careful monitoring of electrolytes and renal function is essential
This understanding of hydrochlorothiazide's renal elimination pathway is crucial for appropriate dosing and monitoring in patients with varying degrees of kidney function.